Basel, Switzerland, June 22, 2020 – ARTIDIS AG, a clinical stage health-tech company, announced today that its proprietary nanotechnology platform for cancer diagnosis has met the primary endpoint in the “NANO” clinical study.

Our CEO Dr. Marija Plodinec explains what ARTIDIS is all about in a very interesting and inspiring conversation with Alec Santiago. Part one:   Part two:

Basel, Switzerland, December 5th, 2019 – ARTIDIS AG (“ARTIDIS”), a privately held healthtech company, announced today the successful closure of a CHF 8.8 million seed financing in two rounds securing early...